ASCO 2023 | Elucidating novel biomarkers for head and neck cancers

Nabil Saba, MD, FACP, Winship Cancer Institute of Emory University, Atlanta, GA, discusses the latest research in emerging predicative biomarkers for head and neck cancers. PD-L1 and tumor mutational burden (TMB) is an established biomarker for non-nasopharynx cancers, and the spatial distribution of immune cells in the tumor microenvironment has been explored to discover new biomarkers. The presence of B cell antigen specific cells in the stroma has been correlated with positive outcomes in patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.